skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Index

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

Kjeldsen, Sverre E ; Dahlöf, Björn ; Devereux, Richard B ; Julius, Stevo ; Aurup, Peter ; Edelman, Jonathan ; Beevers, Gareth ; De Faire, Ulf ; Fyhrquist, Frej ; Ibsen, Hans ; Kristianson, Krister ; Lederballe-Pedersen, Ole ; Lindholm, Lars H ; Nieminen, Markku S ; Omvik, Per ; Oparil, Suzanne ; Snapinn, Steven ; Wedel, Hans

JAMA, 25 September 2002, Vol.288(12), pp.1491-8 [Peer Reviewed Journal]

Full text available

Citations Cited by
  • Title:
    Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy
  • Author: Kjeldsen, Sverre E ; Dahlöf, Björn ; Devereux, Richard B ; Julius, Stevo ; Aurup, Peter ; Edelman, Jonathan ; Beevers, Gareth ; De Faire, Ulf ; Fyhrquist, Frej ; Ibsen, Hans ; Kristianson, Krister ; Lederballe-Pedersen, Ole ; Lindholm, Lars H ; Nieminen, Markku S ; Omvik, Per ; Oparil, Suzanne ; Snapinn, Steven ; Wedel, Hans
  • Description: Drug intervention in placebo-controlled trials has been beneficial in isolated systolic hypertension. To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH). Double-blind, randomized, parallel-group study conducted in 1995-2001. A total of 1326 men and women aged 55 through 80 years (mean, 70 years) with systolic blood pressure of 160 to 200 mm Hg and diastolic blood pressure of less than 90 mm Hg (mean, 174/83 mm Hg) and ECG-LVH, recruited from 945 outpatient settings in the Nordic countries, the United Kingdom, and the United States. Patients were randomly assigned to receive once-daily losartan (n = 660) or atenolol (n = 666) with hydrochlorothiazide as the second agent in both arms, for a mean of 4.7 years. Composite end point of cardiovascular death, stroke, or myocardial infarction. Blood pressure was reduced by 28/9 and 28/9 mm Hg in the losartan and atenolol arms. The main outcome was reduced by 25% with losartan compared with atenolol, 25.1 vs 35.4 events per 1000 patient-years (relative risk [RR], 0.75; 95% confidence interval [CI], 0.56-1.01; P =.06, adjusted for risk and degree of ECG-LVH; unadjusted RR, 0.71; 95% CI, 0.53-0.95; P =.02). Patients receiving losartan had reductions in the following without a difference in the incidence of myocardial infarction: cardiovascular mortality (8.7 vs 16.9 events per 1000 patient-years; RR, 0.54; 95% CI, 0.34-0.87; P =.01), nonfatal and fatal stroke (10.6 vs 18.9 events per 1000 patient-years; RR, 0.60; 95% CI, 0.38-0.92; P =.02), new-onset diabetes (12.6 vs 20.1 events per 1000 patient-years; RR, 0.62; 95% CI, 0.40-0.97; P =.04), and total mortality (21.2 vs 30.2 events per 1000 patient-years; RR, 0.72; 95% CI, 0.53-1.00; P =.046). Losartan decreased ECG-LVH more than atenolol (P<.001) and was better tolerated. These data suggest that losartan is superior to atenolol for treatment of patients with isolated systolic hypertension and ECG-LVH.
  • Is Part Of: JAMA, 25 September 2002, Vol.288(12), pp.1491-8
  • Identifier: ISSN: 0098-7484 ; PMID: 12243636 Version:1
  • Subjects: Antihypertensive Agents -- Therapeutic Use ; Atenolol -- Therapeutic Use ; Cardiovascular Diseases -- Epidemiology ; Hypertension -- Drug Therapy ; Hypertrophy, Left Ventricular -- Drug Therapy ; Losartan -- Therapeutic Use
  • Language: English
  • Source: MEDLINE/PubMed (U.S. National Library of Medicine)

Searching Remote Databases, Please Wait